Handok
4
14M
4
0.06
1
1
- Areas of investment
Summary
In 1954 was created Handok, which is appeared as Corporate Investor.
The standard case for the fund is to invest in rounds with 10 partakers. Despite the Handok, startups are often financed by Takeda Ventures, Seventure Partners, SBI Japan-Israel Innovation Fund. The meaningful sponsors for the fund in investment in the same round are Takeda Ventures, Seventure Partners, SBI Japan-Israel Innovation Fund.
Among the most successful fund investment fields, there are Health Care, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight BIOMx. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.
The fund is generally included in less than 2 deals every year. The high activity for fund was in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 1
- Exits
- 1
- Rounds per year
- 0.06
- Investments by industry
- Biotechnology (3)
- Health Care (3)
- Therapeutics (2)
- Diabetes (1)
- Software (1) Show 6 more
- Investments by region
-
- Israel (1)
- United States (1)
- South Korea (2)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Group Appearance index
- 0.75
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Spark Biopharma | 25 Nov 2021 | Biotechnology, Health Care, Medical, Chemical | Early Stage Venture | 2M | Seoul, Seoul-t'ukpyolsi, South Korea |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.